



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009

Boston Life Sciences

[View the current Boston Life Sciences Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/2113-Boston+Life+Sciences.html)

(<http://www.bioportfolio.com/bi corporate/2113-Boston+Life+Sciences.html>)

Contact Details:

**85 Main Street
Hopkinton**

Tel: (508) 497-2360
Fax: (508) 497-9964

Email: IR@bostonlifesciences.com

01748

United States of America

Boston Life Sciences, Inc (NASDAQ: BLSI) is a biotechnology company engaged in the research and development of biopharmaceutical products for the diagnosis and treatment of Central Nervous System disorders. Our energy and focus in this area are reflected in several important initiatives. Our molecular imaging program has a product candidate, the ALTROPANE® molecular imaging agent, in phase 3 clinical development. ALTROPANE® is a diagnostic tool intended to aid in differentiating Parkinsonian tremors from non-Parkinsonian or Essential Tremor. ALTROPANE is also being assessed in Phase II trials for diagnosing ADHD. Through our licensing and research collaboration with Children's Hospital Boston, Boston Life Sciences maintains a world-class position in the field of regenerating nerve axons. Our sponsored scientific research in this ground-breaking technology may someday make possible therapies leading to functional recovery following stroke, spinal cord and ocular injuries. Finally, our program in Parkinson's Disease aims to provide a therapeutic solution to managing the symptoms as well as to slowing the progression of the disease.

Press Releases on Boston Life Sciences:

[New Hologic SecurView\(R\)](#)

[DX Diagnostic Workstation](#)

[Software Streamlines](#)

[Workflow, Improves](#)

[Radiologist Productivity](#)

25th November, 2009 Hologic, Inc.

BEDFORD, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems

[Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb\(TM\) Technology](#)

25th November, 2009

Sentinelle Medical Inc.

TORONTO, Nov. 25 /PRNewswire/ - Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and advanced visualization software launches a suite of new leading edge clinical applications on

[Sentinelle Medical Inc. Introduces Aegis\(TM\) Web Powered By Calgary Scientific's PureWeb Technology](#)

25th November, 2009

Sentinelle Medical Inc.

TORONTO and CALGARY, Nov. 25 /PRNewswire/ - Sentinelle Medical Inc., a leading manufacturer of Magnetic Resonance Imaging (MRI) coils and software and Calgary Scientific Inc., a leading provider of

[Phonak Successfully Hosts Hearing Care for Adults 2009 Conference](#)

25th November, 2009 Phonak

CHICAGO and STAFFA, Switzerland, Nov. 25 /PRNewswire/ -- From November 16-18, Phonak, the leading manufacturer of innovative hearing solutions, presented the second edition of the Hearing Care for

[The Lupus Foundation of America Hosts Special Webinar to Discuss BENLYSTA\(TM\) Results](#)

25th November, 2009

Lupus Foundation of America

WHAT: The Lupus Foundation of America (LFA) invites those living with lupus to a special Webinar with LFA's Medical Director, Dr. Joan Merrill. Human Genome Sciences (HGS) and GlaxoSmithKline

BioNews Results for Boston Life Sciences



- [Ym Biosciences Announces Nimotuzumab Results In Advanced Triple-negative Breast Cancer Model Presented At Aacr](#)
PR Newswire: Nov 23 2009 12:47AM Matching: boston life sciences
- [Cambridge-based Ligon Discovery Raises \\$1M in Seed Funding](#)
BioSpace: Nov 21 2009 12:38AM Matching: boston life sciences
- [Ym Biosciences Announces Nimotuzumab Results In Advanced Triple-negative Breast Cancer Model Presented At Aacr](#)
Genetic Engineering News: Nov 21 2009 4:47AM Matching: boston life sciences
- [A Week of Woe for Genzyme, A CPR App for Your iPhone, A Better Treatment for Opioid Dependence, and More Boston-Area Life Sciences News](#)
Xconomy: Nov 19 2009 7:14AM Matching: boston life sciences

- [YM Biosciences Announces Nimotuzumab Results In Advanced Triple-Negative Breast Cancer Model Presented At AACR](#)
Pharma Live: Nov 19 2009 9:15AM Matching: boston life sciences
- [Autism Consortium: Autism Consortium symposium draws record number of researchers, advocates, parents for autism update](#)
NewsRX: Nov 18 2009 6:17AM Matching: boston life sciences
- [YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING](#)
CNW Telbec: Nov 18 2009 6:54PM Matching: boston life sciences
- [Ym Biosciences Announces Nimotuzumab Results In Advanced Triple-negative Breast Cancer Model Presented At Aacr](#)
Reuters: Nov 18 2009 6:54PM Matching: boston life sciences
- [Ym Biosciences Announces Nimotuzumab Results In Advanced Triple-negative Breast Cancer Model Presented At Aacr](#)
Charlotte Business Journal: Nov 18 2009 6:53PM Matching: boston life sciences
- [Ym Biosciences Announces Nimotuzumab Results In Advanced Triple-negative Breast Cancer Model Presented At Aacr](#)
San Francisco Business Times: Nov 18 2009 6:50PM Matching: boston life sciences
- [Ym Biosciences Announces Nimotuzumab Results In Advanced Triple-negative Breast Cancer Model Presented At Aacr](#)
KSLA: Nov 18 2009 6:50PM Matching: boston life sciences
- [Ym Biosciences Announces Nimotuzumab Results In Advanced Triple-negative Breast Cancer Model Presented At Aacr](#)
Houston Chronicle: Nov 18 2009 6:23PM Matching: boston life sciences
- [YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING](#)
Street Insider: Nov 18 2009 6:14PM Matching: boston life sciences
- [Ym Biosciences Announces Nimotuzumab Results In Advanced Triple-negative Breast Cancer Model Presented At Aacr](#)
StockHouse USA: Nov 18 2009 6:11PM Matching: boston life sciences
- [YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED](#)
PR Newswire via MSN Money: Nov 18 2009 6:00PM Matching: boston life sciences

Boston Life Sciences Clinical Trials:



- [A Safety Study for Cethrin \(BA-210\) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries](#)



Boston Life Sciences Patents:

- 7078385- [Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit I](#)
- 6586401- [Troponin subunit I fragment and homologs thereof](#)
- 6465431- [Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

